GlassScriptPhysician profile
Amy K Falck
NPI 1225295322
$3,087.32
in general payments reported to CMS, 2019-2025
29 companies · $725 in 2025
The $725 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $352 · 2021: $676 · 2022: $297 · 2023: $327 · 2024: $262 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,313.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $610.44 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $429.64 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $400.30 | 2021-2025 | Freestyle Libre 3, Cardiomems |
| Abbvie INC. | $287.62 | 2021-2025 | |
| Astellas Pharma US INC | $213.81 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $156.59 | 2019-2022 | |
| Dexcom, INC. | $151.73 | 2021-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $124.86 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $99.05 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.95 | 2021-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $87.03 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $59.17 | 2020-2025 | Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $55.23 | 2019-2022 | |
| Boston Scientific Corporation | $41.31 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $31.96 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.00 | 2025 | Caplyta |
| Amarin Pharma, INC. | $25.74 | 2020-2021 | |
| Ucb, INC. | $25.54 | 2025 | Zilbrysq |
| Bardy Diagnostics, INC. | $20.00 | 2021 | |
| Corium, LLC | $19.04 | 2025 | Azstarys |
| Sumitomo Pharma America, INC. | $15.52 | 2025 | Gemtesa |
| Eisai INC. | $14.81 | 2020 | |
| Nestle Healthcare Nutrition INC. | $14.72 | 2020 | |
| Mylan Specialty L.P. | $14.47 | 2023 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $14.16 | 2025 | Rexulti |
| Medtronic, INC. | $13.62 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.33 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $13.27 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Falck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.